Fig. 1

Treatment schedule and tumor size. The patient received erlotinib alone, a small molecule EGFR tyrosine kinase inhibitor, for approximately 1 month. The WT1/MUC1-DC vaccine suspension (approximately 1–2 × 10⁷ cells/dose) was administered intradermally to both upper arms at intervals of approximately 14–21 days independent of the erlotinib regimen. At the patient’s request, all 15 vaccine doses were administered following the completion of 699 days of treatment. After 321 days of combination therapy, no tumor was detected. Validation of the tumor’s disappearance persisted for at least 587 days after treatment initiation